AbbVie, J&J’s Imbruvica fails to target in B-Cell lymphoma trial
AbbVie and Johnson & Johnson’s Imbruvica has failed to meet its key target in a late stage study assessing its use in patients with treatment-naïve diffuse large B-cell lymphoma.
Read More
